Innovations and Challenges in Prostate Cancer: Defining and Treating "High Risk" Disease
Fifth Cambridge Conference - November 2005
This educational program was directed by Peter Carroll, MD, Chairman, Department of Urology, University of California, San Francisco; Ian Thompson, MD, Chair, Department of Urology, The University of Texas Health Science Center at San Antonio; and Michael Carducci, MD, Department of Urology, Johns Hopkins Medical Center.
Educational Objectives
The educational objectives for the enduring CME activity are to: define “high risk” patients with localized and recurrent disease, assess recommendations for treating “high risk” localized disease, assess recommendations for treating “high risk” recurrent disease, and list major ongoing national clinical trials appropriate for high risk patients.
Educational Grant Support
The program was supported by educational grants provided by: Abbott Laboratories, Aventis Pharmaceuticals, AstraZeneca Pharmaceuticals, Novartis Pharmaceuticals, Cell Genesys and Dendreon Corporation.
Sponsorship
CME sponsorship and program management are provided by InforMEDical.
The conference proceedings were published as a peer-reviewed CME supplement to The Journal of Urology, Vol 176, No 6, Part 2 of 2, December 2006.
Journal Website
(subscription may be required to access full journal supplement)
